Imperial College London

Professor Lefkos Middleton

Faculty of MedicineSchool of Public Health

Chair in Clinical Neurology
 
 
 
//

Contact

 

+44 (0)20 3311 7290l.middleton CV

 
 
//

Assistant

 

Ms Naia Headland-Vanni +44 (0)20 3311 7290

 
//

Location

 

Room 10L05 LaboratoryCharing Cross HospitalCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Burns:2021:10.1016/S1474-4422(21)00043-0,
author = {Burns, DK and Alexander, RC and Welsh-Bohmer, KA and Culp, M and Chiang, C and O'Neil, J and Evans, RM and Harrigan, P and Plassman, BL and Burke, JR and Wu, J and Lutz, MW and Haneline, S and Schwarz, AJ and Schneider, LS and Yaffe, K and Saunders, AM and Ratti, E},
doi = {10.1016/S1474-4422(21)00043-0},
journal = {LANCET NEUROLOGY},
pages = {537--547},
title = {Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial},
url = {http://dx.doi.org/10.1016/S1474-4422(21)00043-0},
volume = {20},
year = {2021}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AU - Burns,DK
AU - Alexander,RC
AU - Welsh-Bohmer,KA
AU - Culp,M
AU - Chiang,C
AU - O'Neil,J
AU - Evans,RM
AU - Harrigan,P
AU - Plassman,BL
AU - Burke,JR
AU - Wu,J
AU - Lutz,MW
AU - Haneline,S
AU - Schwarz,AJ
AU - Schneider,LS
AU - Yaffe,K
AU - Saunders,AM
AU - Ratti,E
DO - 10.1016/S1474-4422(21)00043-0
EP - 547
PY - 2021///
SN - 1474-4422
SP - 537
TI - Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
T2 - LANCET NEUROLOGY
UR - http://dx.doi.org/10.1016/S1474-4422(21)00043-0
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000687268300013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL - 20
ER -